ClinicalTrials.gg
RecruitingNCT07101601Updated Aug 3, 2025

Study of DM5167 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of DM5167 in Advanced Breast Cancer, sponsored by DIGMBIO. Recruiting at 4 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by DIGMBIO · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Oct 2024, registered Jul 2025).
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 617 studies in Breast Neoplasms with a site in Korea, Republic of — 133 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.

Planned enrollment
424th of 505
58 · median 218
Started
2024
with 36 others
Phase 1
50 of 617
7 open now
Primary completion
2026-10
later than 93 of 229 live
Registered
586th of 617
by date

Among the 617 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 424th largest by planned enrollment of the 505 interventional ones that give a count, is one of 37 that started in 2024, is one of 50 in phase 1, reaches primary completion later than 93 of the 229 other live ones, and was the 586th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

133 of the 617 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

128 more — sign in →

All 133 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 617 studies in Breast Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety.

The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 19 years or older as of the date of written
  • Patients who have at least one according to version 1.1
  • performance status ≤ 1
  • Patients with ≥ 12 weeks
  • Patients who meet the clinical laboratory test criteria confirming adequate liver, renal, and hematologic function
  • Patients who voluntarily provide written informed consent to participate in this study
  • Patients with or cytologically confirmed unresectable advanced solid tumors
  • Patients who have BRCA1/BRCA2 mutations

Exclusion criteria

Exclusion Criteria:

  • Patients with a medical history of significant illness
  • Patients with of > 450 ms (for men) or > 460 ms (for women)\
  • Patients who have not yet recovered from toxicity related to previous anticancer therapy
  • Patients were predicted to demonstrate to the components of the medicinal product
  • Patients who have participated in another clinical trial and received an investigational product or medical device
  • Other individuals deemed inappropriate for participation in the study by the investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose-escalation Cohort 1

    The first level of dose of DM5167

    Drug: DM5167

  • Experimental
    Part 1: Dose-escalation Cohort 2

    The second level of dose of DM5167

    Drug: DM5167

  • Experimental
    Part 1: Dose-escalation Cohort 3

    The third level of dose of DM5167

    Drug: DM5167

  • Experimental
    Part 1: Dose-escalation Cohort 4

    The fourth level of dose of DM5167

    Drug: DM5167

  • Experimental
    Part 1: Dose-escalation Cohort 5

    The fifth level of dose of DM5167

    Drug: DM5167

  • Experimental
    Part 1: Dose-escalation Cohort 6

    The sixth level of dose of DM5167

    Drug: DM5167

  • Experimental
    Part 2: Dose-expansion Cohort

    The recommended Phase 2 dose of DM5167

    Drug: DM5167

Interventions

  • DrugDM5167

    Once daily for 28 days

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence of dose limiting toxicities (DLT) of DM5167

    Determined by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0

    Time frame: During the first cycle (28 days) of DM5167 treatment

  2. Part 1 and Part 2: Treatment emergent adverse events (TEAE) and serious adverse events (SAEs)

    Clinically significant changes in vital signs, physical examination, ECG and clinical laboratory tests graded by NCI CTCAE v5.0

    Time frame: First dose up to 28 days post end of treatment

Secondary outcomes

  1. Area Under Curve (AUC) of DM5167

    AUC from the time of dosing to the time of the last measurable concentration

    Time frame: - Cycle 1 - Day 1 & Day 15: pre-dose (0h) and up to 24 h post administration of DM5167 - Cycle 3, 5, 7 - Day 1: pre-dose

  2. Objective response rate (ORR)

    The proportion of subjects with best overall response (BOR) evaluated by RECIST version 1.1

    Time frame: Through study completion, an average of 1 year

  3. Maximum Concentration (Cmax) of DM5167

    Maximum observed concentration after administration

    Time frame: - Cycle 1 - Day 1 & Day 15: pre-dose (0h) and up to 24 h post administration of DM5167 - Cycle 3, 5, 7 - Day 1: pre-dose

Other outcomes

  1. PARP inhibition in blood

    Change in poly (ADP-ribose) (PAR) levels in peripheral blood mononuclear cells (PBMCs))

    Time frame: Cycle 1, 2, 3, 5, 7 - Day 1: before the administration of DM5167

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to concerns regarding patient privacy, confidentiality, and compliance with applicable data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 24 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 3, 2025
StartActual
Oct 24, 2024
Primary completionEst.
Oct 30, 2026
CompletionEst.
Jan 31, 2027
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07101601
Lead sponsor
DIGMBIO
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Oct 24, 2024
Primary completion
Oct 30, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Aug 3, 2025

Study contacts

MyungEun Jung
Contact
myungeun@digmbio.com
+82 31 757 220

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion